Table 4.
Comparison of the included interventions for PFS: hazard ratio (95% CrI). Each cell gives the effect of the column-defining intervention relative to the row-defining intervention
| FP | 0.798 ( 0.401, 1.601) | 0.640 ( 0.274, 1.556) | 0.630 ( 0.210, 1.927) | 0.841 ( 0.409, 1.705) | 0.755 ( 0.355, 1.558) | 0.773 ( 0.362, 1.635) | 0.646 ( 0.240, 1.713) | 0.454 ( 0.166, 1.239) | 1.076 ( 0.371, 3.027) |
|---|---|---|---|---|---|---|---|---|---|
| FP + LV* | 0.804 ( 0.478, 1.395) | 0.787 ( 0.334, 1.921) | 1.051 ( 0.385, 2.823) | 0.944 ( 0.343, 2.603) | 0.964 ( 0.347, 2.719) | 0.808 ( 0.400, 1.623) | 0.56 ( 0.27, 1.15) | 1.342 ( 0.372, 4.635) | |
| FP + LV + OXA | 0.981 ( 0.483, 1.960) | 1.314 ( 0.412, 4.008) | 1.174 ( 0.365, 3.601) | 1.198 ( 0.365, 3.849) | 1.009 ( 0.403, 2.386) | 0.709 ( 0.285, 1.708) | 1.665 ( 0.407, 6.489) | ||
| FP + LV + OXA + PEG | 1.341 ( 0.351, 5.044) | 1.202 ( 0.314, 4.528) | 1.223 ( 0.311, 4.676) | 1.031 ( 0.335, 3.043) | 0.727 ( 0.228, 2.197) | 1.700 ( 0.358, 7.645) | |||
| S1 + OXA | 0.894 ( 0.319, 2.506) | 0.916 ( 0.327, 2.599) | 0.769 ( 0.230, 2.555) | 0.538 ( 0.158, 1.820) | 1.270 ( 0.358, 4.648) | ||||
| CAPE + ruxolitinib | 1.023 ( 0.349, 2.925) | 0.864 ( 0.260, 2.898) | 0.602 ( 0.178, 2.063) | 1.426 ( 0.387, 5.229) | |||||
| IRINOTECAN + FP° | 0.835 ( 0.249, 2.858) | 0.584 ( 0.167, 2.079) | 1.394 ( 0.647, 2.901) | ||||||
| NALIRI | 0.701 ( 0.256, 1.928) | 1.654 ( 0.387, 6.851) | |||||||
| NALIRI + FP + LV | 2.379 ( 0.540, 10.164) | ||||||||
| Veliparib + IRINOTECAN + FP |
*, include also S1 + leucovorin doublet; °, include FOLFIRI and S1 + irinotecan;